Padua Prediction Score Calculator

About the Padua Prediction Score Calculator

The Padua Prediction Score is a widely used risk assessment model for venous thromboembolism (VTE) in medical inpatients. Published by Barbar et al. in 2010, it uses 11 clinical risk factors to identify hospitalized medical patients who sit in higher- or lower-risk VTE bands.

Hospital-associated VTE accounts for a large share of overall DVT and PE events. Systematic risk assessment helps separate patients who may need closer prevention review from those whose care is more often centered on mobility and routine inpatient measures.

A Padua score ≥4 identifies patients with a substantially higher 30-day VTE risk than patients with scores <4. That threshold is commonly used to frame prevention discussions, but bleeding risk, contraindications, and local protocols still need separate review before a plan is chosen.

When This Page Helps

Pharmacologic VTE prevention is not risk-free, so a broad "treat everyone" approach is not ideal for medical inpatients. The Padua score helps structure who falls into a higher-risk versus lower-risk VTE context.

The score is most useful when read alongside bleeding-risk tools, current mobility, and the broader admission picture rather than as a stand-alone prophylaxis order engine.

How to Use the Inputs

1. Assess each of the 11 VTE risk factors at admission.
2. Major factors (3 points each): cancer, prior VTE, immobility, thrombophilia.
3. Note recent surgery or trauma (2 points).
4. Evaluate minor factors (1 point each): age, heart failure, infection, obesity, hormonal therapy.
5. Sum all points for the total Padua score.
6. Score ≥4: treat this as a higher-risk context and review prevention options after bleeding-risk assessment.
7. Reassess daily and with any change in clinical condition.

Example Calculation

Tips & Best Practices

• Assess bleeding risk alongside the Padua score before turning the result into a prevention plan.
• Cancer patients with central venous catheters have compounding VTE risk — consider this when scoring.
• Mechanical and pharmacologic prevention decisions depend on the wider clinical picture, not Padua alone.
• Patients admitted with stroke, renal impairment, or active bleeding concerns often need more individualized review than a single score can provide.
• Reassess Padua score daily — risk factors change during hospitalization.
• Document the Padua score and prophylaxis decision in the medical record for regulatory compliance.

What the Padua Score Does Well

The Padua score is good at splitting medical inpatients into lower- and higher-risk VTE groups using variables that are usually available on admission. That makes it useful for structured bedside review and quality-improvement workflows.

What the Score Does Not Do

The score does not measure bleeding risk, does not account for every contraindication, and does not replace local policy. It should be paired with a bleeding-risk review and the broader clinical picture before any prevention strategy is finalized.

Special Populations

Critically ill patients, pregnant patients, and patients with unusual thrombosis or bleeding disorders often need tools or pathways beyond Padua alone. In those groups, the score is best treated as one input rather than the entire decision framework.

Frequently Asked Questions

• Does the Padua score apply to surgical patients?

  No. The Padua score was developed and validated for MEDICAL inpatients. Surgical patients should use the Caprini score or Rogers score, which account for procedure-specific risk factors (type of surgery, duration, anesthesia type). Surgical VTE prophylaxis follows separate guidelines.

• What if the patient is at high VTE risk but also high bleeding risk?

  That is exactly why the Padua score should not be used by itself. Bleeding risk, contraindications, and local protocols need to be reviewed alongside the Padua result before a prevention plan is chosen.

• How long should prophylaxis continue?

  Standard duration: throughout the hospital stay and until the patient is fully mobile. Extended prophylaxis (up to 45 days) may benefit select higher-risk patients (the EXCLAIM and MARINER trials showed modest benefit in high-risk subgroups, but with increased bleeding). Extended-duration betrixaban was FDA-approved based on APEX trial data.

• Which anticoagulant is preferred for prophylaxis?

  That depends on renal function, bleeding risk, local policy, and the broader inpatient picture. This page keeps the discussion at risk-stratification level rather than acting as a medication order sheet.

• What counts as "reduced mobility"?

  Bed rest with bathroom privileges for an anticipated ≥3 days. This includes patients who are too ill to ambulate, those on strict bed rest for medical reasons, and patients with conditions that severely limit mobility (e.g., paralysis, severe pain). Brief periods out of bed for toileting alone still qualify.

• Does aspirin count as VTE prophylaxis?

  For medical inpatients, aspirin is NOT considered adequate VTE prophylaxis. While low-dose aspirin has shown some benefit in post-surgical VTE prevention (EPCAT II, CRISTAL trials), it is significantly less effective than LMWH for medical thromboprophylaxis. Patients on aspirin for cardiac indications who are Padua ≥4 should receive LMWH prophylaxis.